Showing results (1241-1250 of 3,869) with videos related to
Sort By:
Pageof 387
Cancer Biology & Therapy|January 26, 2011
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancerJinhong Feng, Hao Fang, Xuejian Wang, et al.Cancer Biology & Therapy|October 12, 2010
Inhibition of NADPH oxidase by glucosylceramide confers chemoresistanceBrian M Barth, Sally J Gustafson, Megan M Young, et al.Cancer Biology & Therapy|October 12, 2010
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Tetyana V Bagnyukova, Ilya G Serebriiskii, Yan Zhou, et al.Cancer Biology & Therapy|October 12, 2010
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experienceImmacolata Capasso, Emanuela Esposito, Francesca Pentimalli, et al.Cancer Biology & Therapy|September 22, 2010
The role of microenvironment in testicular germ cell tumorsAlejandro Díez-Torre, Unai Silván, María Díaz-Núñez, et al.Cancer Biology & Therapy|September 22, 2010
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabineZhian Liu, Alberto Fusi, Alexander Schmittel, et al.Cancer Biology & Therapy|September 22, 2010
Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancerMasafumi Takeshita, Takaomi Koga, Koichi Takayama, et al.Cancer Biology & Therapy|November 19, 2010
Astrocyte-elevated gene-1 (AEG-1) induction by hypoxia and glucose deprivation in glioblastomaEvan Noch, Markus Bookland, Kamel KhaliliCancer Biology & Therapy|November 20, 2010
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancersSrikumar M Raja, Robert J Clubb, Cesar Ortega-Cava, et al.Cancer Biology & Therapy|November 25, 2010
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD studyCarlos Hörndler, Rosa Gallego, Xabier García-Albeniz, et al.Pageof 387